[{"type": "title", "data": "Venous Thromboembolism (VTE) Prophylaxis (Module)"}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "For obstetrical patients, refer to OB Postpartum VTE Thromboprophylaxis (Module)", "value": ""}, {"type": "note", "data": "For patients receiving prophylactic subcutaneous enoxaparin up to 40 mg qdaily or dalteparin up to 5000 units qdaily or heparin up to 5000 units Q8H:\n-Do not remove epidural/perineural catheter for at least 12 hours after the last dose of LMWH (enoxaparin or dalteparin) and at least 4 hours after the last dose of heparin\n-After catheter removal, do not administer LMWH (enoxaparin or dalteparin) for at least 4 hours and heparin for at least 1 hour", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "Refer to VTE Risk Assessment and Thromboprophylaxis Recommendation", "value": ""}, {"type": "note", "data": "Epidural catheter should not be removed for at least 12 or more hours after a dose of enoxaparin or heparin", "value": ""}, {"type": "note", "data": "After epidural catheter removal, enoxaparin or heparin should not be given for at least 4 hours", "value": ""}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "For patients receiving prophylactic subcutaneous enoxaparin up to 40 mg qdaily or dalteparin up to 5000 units qdaily or heparin up to 5000 units Q8H:\n-Do not remove epidural/perineural catheter for at least 12 hours after the last dose of LMWH (enoxaparin or dalteparin) and at least 4 hours after the last dose of heparin\n-After catheter removal, do not administer LMWH (enoxaparin or dalteparin) for at least 4 hours and heparin for at least 1 hour"}, {"type": "note", "data": "Heparin 5000 units subcutaneous q12h should be used if patient is awaiting urgent surgery and is a candidate for neuraxial blockade", "value": ""}, {"type": "order", "data": "VTE Prophylaxis Contraindication", "value": ""}, {"type": "sentence", "data": "Contraindications: Active bleeding requiring intervention"}, {"type": "sentence", "data": "Contraindications: Risk of serious bleed in critical site"}, {"type": "sentence", "data": "Contraindications: Known major bleed disorder/coagulopathy"}, {"type": "sentence", "data": "Contraindications: Platelet count less than 50 x 10^9/L"}, {"type": "sentence", "data": "Contraindications: Hx of heparin-induced thrombocytopenia"}, {"type": "sentence", "data": "Contraindications: Receiving therapeutic anticoagulant"}, {"type": "note", "data": "VTE RISK IS LOW", "value": ""}, {"type": "note", "data": "No anticoagulant or mechanical prophylaxis required. Encourage early ambulation for patient", "value": ""}, {"type": "order", "data": "Ambulate", "value": ""}, {"type": "sentence", "data": "No anticoagulant or no mechanical prophylaxis required"}, {"type": "note", "data": "VTE RISK IS MODERATE OR HIGH WITHOUT CONTRAINDICATION TO ANTICOAGULANTS - MEDICAL PATIENTS", "value": ""}, {"type": "note", "data": "For surgical patients, please mark the time and date of the first post-op dose on the respective medication order. For spinal surgery patients, recommended to order first post-op dose 24 hours after admission to PACU", "value": ""}, {"type": "note", "data": "Patient does not require additional in-hospital pharmacologic thromboprophylaxis because patient requires anticoagulation for another indication", "value": ""}, {"type": "note", "data": "Anticoagulants contraindicated in:   - Active bleeding of clinical significance requiring intervention   - High risk of serious bleeding or bleeding into a critical site (e.g. intracranial, epidural, pericardial, intraocular, retroperitoneal, intra-articular)   - Known major bleeding disorder or acquired coagulopathy (consider Hematology consult)   - Platelet count less than 50 x 10^9/L (consider Hematology consult)   - History of heparin induced thrombocytopenia (HIT) (fondaparinux allowed)", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "Enoxaparin q12h dosing is contraindicated if patient requires epidural analgesia", "value": ""}, {"type": "note", "data": "Enoxaparin for eGFR 30 mL/min or greater", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "30 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "40 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, q12h, drug form: syringe-inj"}, {"type": "sentence", "data": "40 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "60 mg, subcutaneous, q12h, drug form: syringe-inj"}, {"type": "sentence", "data": "60 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Enoxaparin for eGFR 10 to 29 mL/min", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "30 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "40 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "60 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "60 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Heparin for eGFR less than 10 mL/min or on dialysis", "value": ""}, {"type": "order", "data": "heparin", "value": ""}, {"type": "sentence", "data": "2,500 unit, subcutaneous, q12h, drug form: inj"}, {"type": "sentence", "data": "2,500 unit, subcutaneous, q12h, drug form: inj, start: T+1;1000"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: inj"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: inj, start: T+1;1000"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q8h, drug form: inj"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q8h, drug form: inj, start: T+1;0600"}, {"type": "note", "data": "Enoxaparin for patients with high risk poly-trauma / skeletal trauma; contraindicated if epidural to be placed or in situ for neuraxial blockade:", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, q12h, drug form: syringe-inj"}, {"type": "sentence", "data": "30 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Fondaparinux for patients with heparin-induced thrombocytopenia; contraindicated if epidural to be placed or in situ:", "value": ""}, {"type": "order", "data": "fondaparinux", "value": ""}, {"type": "sentence", "data": "2.5 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "2.5 mg, subcutaneous, qdaily, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Rivaroxaban restricted for post-hip or knee arthroplasty; contraindicated if epidural to be placed or in situ or e-GFR is less than 30 mL/min. Please specify number of days within medication order", "value": ""}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qdaily, order duration: 14 day, drug form: tab"}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qdaily, order duration: 14 day, drug form: tab, start: T+1;1000"}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qdaily, order duration: 35 day, drug form: tab"}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qdaily, order duration: 35 day, drug form: tab, start: T+1;1000"}, {"type": "note", "data": "VTE RISK IS MODERATE OR HIGH WITHOUT CONTRAINDICATION TO ANTICOAGULANTS - SURGICAL PATIENTS", "value": ""}, {"type": "note", "data": "For surgical patients, please mark the time and date of the first post-op dose on the respective medication order. For spinal surgery patients, recommended to order first post-op dose 24 hours after admission to PACU", "value": ""}, {"type": "note", "data": "Patient does not require additional in-hospital pharmacologic thromboprophylaxis because patient requires anticoagulation for another indication", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "Anticoagulants contraindicated in:   - Active bleeding of clinical significance requiring intervention   - High risk of serious bleeding or bleeding into a critical site (e.g. intracranial, epidural, pericardial, intraocular, retroperitoneal, intra-articular)   - Known major bleeding disorder or acquired coagulopathy (consider Hematology consult)   - Platelet count less than 50 x 10^9/L (consider Hematology consult)   - History of heparin induced thrombocytopenia (HIT) (fondaparinux allowed)", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "Epidural is contraindicated if enoxaparin dose exceeds 40 mg daily or dalteparin dose exceeds 5000 units daily", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "Enoxaparin for eGFR 30 mL/min or greater", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "60 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Enoxaparin for eGFR 10 to 29 mL/min", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "60 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Heparin for eGFR less than 10 mL/min or on dialysis", "value": ""}, {"type": "order", "data": "heparin", "value": ""}, {"type": "sentence", "data": "2,500 unit, subcutaneous, q12h, drug form: inj"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: inj"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q8h, drug form: inj"}, {"type": "note", "data": "Enoxaparin for patients with high risk poly-trauma / skeletal trauma; contraindicated if epidural to be placed or in situ for neuraxial blockade:", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Fondaparinux for patients with heparin-induced thrombocytopenia; contraindicated if epidural to be placed or in situ:", "value": ""}, {"type": "order", "data": "fondaparinux", "value": ""}, {"type": "sentence", "data": "2.5 mg, subcutaneous, qdaily, drug form: syringe-inj"}, {"type": "sentence", "data": "2.5 mg, subcutaneous, qdaily, drug form: syringe-inj, start: T+1;1000"}, {"type": "note", "data": "Rivaroxaban restricted for post-hip or knee arthroplasty; contraindicated if epidural to be placed or in situ or e-GFR is less than 30 mL/min. Please specify number of days within medication order", "value": ""}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qdaily, order duration: 14 day, drug form: tab,  start: T+1;1000"}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qdaily, order duration: 35 day, drug form: tab, start: T+1;1000"}, {"type": "note", "data": "Bridging to Low Molecular Weight Heparin", "value": ""}, {"type": "order", "data": "heparin", "value": ""}, {"type": "sentence", "data": "2,500 unit, subcutaneous, once, drug form: inj"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once,  drug form: inj"}, {"type": "note", "data": "VTE RISK IS MODERATE OR HIGH WITH CONTRAINDICATION TO ANTICOAGULANTS", "value": ""}, {"type": "note", "data": "Mechanical prophylaxis contraindicated in:  - Peripheral vascular disease with absent pedal pulses  - Severe peripheral neuropathy  - Skin breakdown, ulcers, gangrene, cellulitis, or dermatitis  - Skin grafting within last 3 months  - Allergy to stocking or compression cuff materials  - Unable to size or apply properly due to deformity, recent surgery or trauma  - Only graduated compression stocking is contraindicated for acute stroke with immobility (unable to walk independently to the toilet)", "value": ""}, {"type": "order", "data": "Apply Full Leg Sequential Compression Devices", "value": ""}, {"type": "sentence", "data": "Apply to lower limb(s) continuously until anticoagulant prophylaxis starts or discharge. Interrupt for skin care, assessments, toileting, and ambulation only"}, {"type": "order", "data": "Apply Below the Knee Sequential Compression Devices", "value": ""}, {"type": "sentence", "data": "Apply to lower limb(s) continuously until anticoagulant prophylaxis starts or discharge. Interrupt for skin care, assessments, toileting, and ambulation only"}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No mechanical prophylaxis because of contraindication(s)"}, {"type": "note", "data": "ASA EC for post hip or knee surgery if on mechanical prophylaxis only", "value": ""}, {"type": "order", "data": "ASA EC", "value": ""}, {"type": "sentence", "data": "162 mg, PO, qdaily with food, drug form: tab-EC"}]
